Restoring corneal tissue strength for treatment of degenerative eye diseases
- Summary
- Although corneal collagen crosslinking is an effective method for treating degenerative eye diseases such as progressive myopia glaucoma, and keratoconus, current crosslinking methods are limited by poor tissue penetration, high potential for infection, and risk of damage to surrounding tissues. This technology is a method of crosslinking collagenous tissues using formaldehyde-releasing agents. This therapeutic approach can be used to restore corneal tissue strength while avoiding the risks associated with existing treatment methods.
- Technology Benefits
- Potent crosslinking agentProven safety record in consumer productsAvoids exposure to potentially harmful UV light and risky surgical proceduresBroad, non-ophthalmologic applicationsPatent Information:Patent Pending (US 20160374992)Tech Ventures Reference: IR CU14195
- Technology Application
- Corneoscleral tissue crosslinking agentTherapeutic for treatment of keratoconus and other degenerative eye diseasesTreatment for patients with myopia or nearsightednessTreatment for ecstasia associated with eye surgeries including LASIK (Laser-Assisted In-Situ Keratomileusis) or PRK (Photorefractive Keratectomy)Restoring strength in collagenous tissues, including but not limited to, the cornea, sclera, heart valves, skin, tendons, fascia, bone, and cartilage
- Detailed Technology Description
- None
- *Abstract
-
None
- *Inquiry
- Sara GusikColumbia Technology VenturesTel: (212) 854-8444Email: TechTransfer@columbia.edu
- *IR
- CU14195
- *Principal Investigator
-
- Country/Region
- USA
For more information, please click Here
